Spiden Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
This is a single-centre, multiple sequential-cohort, open study.
- EligibilityCriteria: Inclusion Criteria:  Male or female trial participant with clinically diagnosed type 1 or type 2 diabetes for at least 1 year. Age between 18 and 65 years, both inclusive. Treated with basal insulin or basal insulin and oral antidiabetic drugs (OADs; type 2 only), multiple dosing insulin therapy (MDI), continuous subcutaneous insulin infusion (CSII) or a hybrid closed loop system.  Exclusion Criteria:  Known or suspected hypersensitivity to any of the components of the Spiden Clinical Demo 2.0. Trial participant with any injury, infection, atypical skin condition (e.g., hyperkeratosis, hyperpigmentation) of or tattoo on the wrists. Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult